Advertisment

FDA Approves Ogsiveo, a Groundbreaking Treatment for Desmoid Tumors

author-image
Zara Nwosu
New Update
NULL

FDA Approves Ogsiveo, a Groundbreaking Treatment for Desmoid Tumors

Advertisment

A Game-Changer in the Treatment of Desmoid Tumors

Advertisment

The US Food and Drug Administration (FDA) has recently granted approval for Ogsiveo (nirogacestat), a new treatment option for desmoid tumors. Developed by SpringWorks Therapeutics, Ogsiveo is an oral gamma-secretase inhibitor specifically designed to address these rare, non-cancerous but locally invasive soft-tissue tumors. Prior to this, treatment options were limited to off-label use of chemotherapy and tyrosine kinase inhibitors.

Desmoid Tumors and Their Impact

Desmoid tumors, while not cancerous, can cause significant health issues. They lead to pain, reduce mobility, and negatively impact the quality of life of patients. Despite their non-malignant nature, they are locally invasive, making the development of effective treatment methods a medical necessity. The approval of Ogsiveo is a significant breakthrough in this regard.

Advertisment

The Journey of Ogsiveo to FDA Approval

Ogsiveo's approval was based on the results of the phase III DeFi study. This study demonstrated that treatment with Ogsiveo led to significant antitumor activity and an improvement in desmoid tumor symptoms. SpringWorks Therapeutics' shares rose by 18.7% following the announcement of Ogsiveo's FDA approval. The drug is the first to receive approval for treating desmoid tumors, potentially setting a new standard of care for these patients.

Ongoing Studies and Future Plans

Advertisment

SpringWorks Therapeutics is not stopping at desmoid tumors. Other studies are currently ongoing to determine Ogsiveo's efficacy in treating different cancer indications. Moreover, a marketing authorization application for Ogsiveo in desmoid tumors is expected to be filed in the European Union in the first half of 2024, expanding its potential reach to more patients in need.

Ogsiveo's Cost and Accessibility

While the introduction of Ogsiveo is a significant medical advancement, its pricing is a crucial factor for patients. Ogsiveo is priced at around $30,547 for a supply of 180 tablets. However, there are various financial assistance options available for eligible patients. These include coupons, rebates, and patient assistance programs that can significantly lower the cost of this prescription. Some of these programs can reduce the cost by up to 80% or more, making the treatment more accessible for low-income individuals or those who are uninsured or under-insured.

Advertisment

Efficacy and Safety of Ogsiveo

The FDA approval of Ogsiveo was not just based on its efficacy, but also its safety profile. Clinical trials have shown that Ogsiveo is not only effective in reducing the size of the tumors and improving the symptoms, but it is also well-tolerated by patients. This combination of efficacy and safety makes Ogsiveo a promising treatment for desmoid tumors.

Conclusion

The FDA's approval of Ogsiveo marks a significant milestone in the treatment of desmoid tumors. For the first time, there is a drug specifically approved for this condition, potentially transforming the lives of patients struggling with these tumors. Despite the high cost, various financial assistance programs can make this treatment accessible to a wide range of patients. With ongoing studies and plans for application in the European Union, the future looks promising for Ogsiveo and the patients it serves.

Advertisment
Chat with Dr. Medriva !